Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02515630 | Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | PHASE2 | COMPLETED | 41 | — | — | Jan 29, 2016 | Aug 15, 2017 | Jun 18, 2023 | 13 | United States, Canada |
The percentage of subjects who became transfusion independent for ≥ 12 weeks at any time on study. A subject was considered transfusion independent on study if no RBC transfusion occurred in any 12-week period during the 24-week treatment period.
| Arm | Type | Description |
|---|---|---|
| Momelotinib | EXPERIMENTAL | MMB for 24 weeks (± 7 days) |
| Name | Type | Description |
|---|---|---|
| MMB | DRUG | Momelotinib (MMB) tablet administered orally once daily |
Key Inclusion Criteria: * Diagnosis of PMF or Post PV/ET-MF * Requires myelofibrosis therapy, in the opinion of the investigator * High risk OR intermediate-2 risk defined by dynamic international prognostic scoring system (DIPSS) OR intermediate-1 risk defined by DIPSS and associated with symptoma...